Our data indicated that transgelin acts as a proto-oncogene rather than as a tumor suppressor gene in NF1-associated MPNST development, which suggests that transgelin may be a suitable target molecule to be inhibited for therapeutic treatment and/or prevention of MPNSTs. Here, NF1 is linked to malignant peripheral nerve sheath tumor.